UroGen Pharma (NASDAQ:URGN) and Acelyrin (NASDAQ:SLRN) Head to Head Contrast

Acelyrin (NASDAQ:SLRN) and UroGen Pharma (NASDAQ:URGN) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, risk, analyst recommendations, valuation, institutional ownership and profitability.

Analyst Recommendations

This is a summary of recent ratings and target prices for Acelyrin and UroGen Pharma, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Acelyrin	0	2	3	0	2.60
UroGen Pharma	0	0	3	0	3.00

Acelyrin currently has a consensus target price of $12.80, indicating a potential upside of 85.51%. UroGen Pharma has a consensus target price of $51.17, indicating a potential upside of 202.05%. Given UroGen Pharma’s stronger consensus rating and higher probable upside, analysts clearly believe UroGen Pharma is more favorable than Acelyrin.

Profitability

This table compares Acelyrin and UroGen Pharma’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Acelyrin	N/A	-35.33%	-32.55%
UroGen Pharma	-123.74%	N/A	-62.48%

Institutional and Insider Ownership

87.3% of Acelyrin shares are owned by institutional investors. Comparatively, 91.3% of UroGen Pharma shares are owned by institutional investors. 13.6% of Acelyrin shares are owned by company insiders. Comparatively, 5.1% of UroGen Pharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Earnings and Valuation

This table compares Acelyrin and UroGen Pharma’s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Acelyrin	N/A	N/A	-$381.64 million	($2.38)	-2.90
UroGen Pharma	$84.30 million	4.71	-$102.24 million	($3.40)	-4.98

UroGen Pharma has higher revenue and earnings than Acelyrin. UroGen Pharma is trading at a lower price-to-earnings ratio than Acelyrin, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Acelyrin has a beta of 2.55, meaning that its stock price is 155% more volatile than the S&P 500. Comparatively, UroGen Pharma has a beta of 1.12, meaning that its stock price is 12% more volatile than the S&P 500.

About Acelyrin

Acelyrin, Inc., a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis. It is also developing lonigutamab, a humanized immunoglobulin G1 (IgG1) monoclonal antibody which is in Phase 1 clinical trials for use in the treatment of thyroid eye disease. In addition, the company's develops SLRN-517, a fully human IgG1 monoclonal antibody targeting c-KIT, which is in preclinical stage for use in the treatment of chronic urticaria. Acelyrin, Inc. was incorporated in 2020 and is headquartered in Agoura Hills, California.

About UroGen Pharma

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102 for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk non-muscle invasive bladder cancer (NMIBC). It is also developing UGN-301 for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; strategic research collaboration agreement with MD Anderson focusing on the sequential use of UGN-201 and UGN-301 for the treatment of NMIBC; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 in low-grade intermediate risk NMIBC and UGN-104 in low-grade upper tract urothelial carcinoma. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.